Activity of heparins in experimental models of malignancy: Possible explanations for anticancer effects in humans

Clinical Hemorheology and Microcirculation

Volumn 26, Issue 1, 2002, Pages 33-40

  Ornstein, Deborah L ^a   Zacharski, Leo R ^a  

^a WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CATHEPSIN G; FIBROBLAST GROWTH FACTOR; HEPARANASE; HEPARIN; HEPARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; MATRIX METALLOPROTEINASE; MIDKINE; PADGEM PROTEIN; PLASMIN; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PLEIOTROPHIN; THROMBIN; TISSUE INHIBITOR OF METALLOPROTEINASE; VASCULOTROPIN;

ANGIOGENESIS; ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CARCINOGENESIS; CELL ADHESION; CONFERENCE PAPER; DRUG SAFETY; DRUG SCREENING; ENZYME ACTIVITY; HUMAN; METASTASIS; NONHUMAN; PROTEIN FUNCTION; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HEPARIN; HUMANS; NEOPLASM METASTASIS; NEOPLASMS;

EID: 0036274353     PISSN: 13860291     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (52)

1. Proteoglycans: Structures and interactions
2. Treatment of corticosteroid-resistant ulcerative colitis with heparin - A report of 16 cases
3. Inhibition of HIV-1 infectivity by low molecular weight heparin. Results of in vitro studies and a pilot clinical trial in patients with advanced AIDS
4. The use of heparin for treating human malignancies
5. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis
6. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread
7. Treatment of deep venous thrombosis with low-molecular weight heparins. A meta-analysis
8. Low-molecular weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
9. The influence of anticlotting agents on transplantation and growth of tumor tissue
10. An experimental study of the influence of adrenal steroids, growth hormone and anticoagulants on pulmonary metastasis formation in mice
11. Actions of heparin that may affect the malignant process
12. Inhibition of metastases by anticoagulants
13. Clinical applications of research on angiogenesis
14. Molecular determinants of angiogenesis in cancer metastasis
15. Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor
16. Mediators of angiogenesis: The biological significance of basic fibroblast growth factor (bFGF)-heparin and heparan sulfate interactions
17. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro
18. Basic fibroblast growth factor-mediated de-novo angiogenesis is more effectively suppressed by low molecular weight than by high molecular weight heparin
19. Modulation of fibroblast growth factor-2 receptor binding, signaling and mitogenic activity by heparin-mimicking polysulfonated compounds
20. Modulation of fibroblast growth factor-2 receptor binding, dimerization, signaling, and angiogenic activity by a synthetic heparin-mimicking polyanionic compound
21. Polysulfated heparinoids selectively inactivate heparin-binding angiogenesis factors
22. Novel heparin derivative that prevents dimerization of FGF-2 and inhibits angiogenesis
23. Heparin oligosaccharides: Inhibitors of the biological activity of bFGF on Caco2 cells
24. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: A prospective randomized double-blind trial
25. 2.5 kDa and 5.0 kDa heparin fragments specifically inhibit microvessel sprouting and network formation in VEGF165-mediated mammalian angiogenesis
26. Pleiotriphin and midkine, a family of mitogenic and angiogenic heparin-binding growth and differentiation factors
27. Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development
28. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors
29. Heparin inhibits the induction of three matrix metalloproteinases (stromelysin, 92-kD gelatinase, and collagenase) in primate arterial smooth muscle cells
30. Heparan sulfate proteoglycans as extracellular docking molecules for matrilysin (matrix metalloproteinase 7)
31. Human tissue inhibitor of metalloproteinases 3 interacts with both the N- and C-terminal domains of gelatinases A and B. Regulation by polyanions
32. Matrix metalloproteinases and tumor invasion: From correlation and causality to the clinic
33. Clinical aspects of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy
34. Antithrombin III- and heparin cofactor II-mediated anticoagulant and antiprotease actions of heparin and its synthetic analogues
35. Interaction of heparin cofactor II with neutrophil elastase and cathepsin G
36. Human fibroblasts accelerate the inhibition of thrombin by protease nexin
37. Inhibition of acrosin by serpins. A suicide substrate mechanism
38. Released protease nexin regulates cellular binding, internalization and degradation of serine proteases
39. Heparanase: Breaking down barriers in tumors
40. Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis
41. Human heparanase: Roles in invasion and metastasis of cancer
42. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties
43. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity
44. Inhibition of tumor metastasis by heparanase inhibiting species of heparin
45. Adhesion molecules and tumor cell interaction with endothelium and subendothelial matrix
46. Mechanisms of metastasis production by blood-borne cancer cells
47. Platelets and cancer metastasis: A causal relationship?
48. P-selectin deficiency attenuates tumor growth and metastasis
49. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents
50. Heparin and cancer revisited: Mechanistic connections iinvolving platelets, P-selectin, carcinoma mucins and tumor metastasis
51. Perioperative heparin therapy inhibits late death from metastatic cancer
52. Peri-operative heparin: A possible adjuvant to surgery in colo-rectal cancer?